Organovo Holdings, Inc. (ONVO) financial statements (2021 and earlier)

Company profile

Business Address 6275 NANCY RIDGE DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End March 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q3
9/30/2019
Q2
6/30/2019
Q1
3/31/2019
Q4
12/31/2018
Q3
9/30/2018
Q2
6/30/2018
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments30303536353740
Cash and cash equivalents30303536353740
Receivables0111101
Inventory, net of allowances, customer advances and progress billings 010111
Inventory 010111
Other undisclosed current assets0111111
Total current assets:31333739374042
Noncurrent Assets
Operating lease, right-of-use asset 4  
Property, plant and equipment 122223
Restricted cash and investments0000000
Other noncurrent assets0000000
Other undisclosed noncurrent assets  4    
Total noncurrent assets:0562233
TOTAL ASSETS:31384341404345
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2223322
Accounts payable1011100
Accrued liabilities2213222
Debt 1     
Deferred rent credit   0000
Contract with customer, liability11111
Other undisclosed current liabilities  1    
Total current liabilities:2344333
Noncurrent Liabilities
Long-term debt and lease obligation 4     
Operating lease, liability 4  
Liabilities, other than long-term debt   1101
Contract with customer, liability  0
Deferred rent credit   1101
Other undisclosed noncurrent liabilities  4    
Total noncurrent liabilities: 441101
Total liabilities:2774444
Stockholders' equity
Stockholders' equity attributable to parent29313636363941
Common stock0000000
Additional paid in capital306304303297289286283
Accumulated deficit(277)(273)(267)(261)(254)(247)(242)
Total stockholders' equity:29313636363941
TOTAL LIABILITIES AND EQUITY:31384341404345

Income statement (P&L) ($ in millions)

12/31/2019
Q3
9/30/2019
Q2
6/30/2019
Q1
3/31/2019
Q4
12/31/2018
Q3
9/30/2018
Q2
6/30/2018
Q1
Revenues0111111
Cost of revenue(1)(0)(0)(0)(0)(0)(0)
Cost of goods and services sold(0)(0)(0)(0)(0)(0)(0)
Gross profit:(0)111111
Operating expenses(5)(8)(7)(8)(7)(7)(8)
Other undisclosed operating income (loss) 00(0)(0)(0)(0)
Operating loss:(5)(7)(7)(7)(7)(6)(8)
Nonoperating income2100000
Investment income, nonoperating0000000
Other nonoperating income10     
Loss from continuing operations before income taxes:(3)(6)(6)(7)(6)(6)(7)
Income tax expense (0)    (0)
Net loss available to common stockholders, diluted:(3)(6)(6)(7)(6)(6)(7)

Comprehensive Income ($ in millions)

12/31/2019
Q3
9/30/2019
Q2
6/30/2019
Q1
3/31/2019
Q4
12/31/2018
Q3
9/30/2018
Q2
6/30/2018
Q1
Net loss:(3)(6)(6)(7)(6)(6)(7)
Comprehensive loss, net of tax, attributable to parent:(3)(6)(6)(7)(6)(6)(7)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: